TAL1 and acute lymphoblastic leukemia: To evaluate this possibility, we used the CRISPR-Cas9 technology targeting exon 6 of USP7 in Jurkat and Molt-4, the T-ALL cell lines that have aberrant TAL1 activation and intact USP7 (Fig. 5A).